辰欣药业
(603367)
| 流通市值：71.89亿 | | | 总市值：72.13亿 |
| 流通股本：4.51亿 | | | 总股本：4.53亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,148,946,834.25 | 4,462,348,636.07 | 3,209,858,058.38 | 2,219,709,781.45 |
| 营业收入 | 1,148,946,834.25 | 4,462,348,636.07 | 3,209,858,058.38 | 2,219,709,781.45 |
| 二、营业总成本 | 954,816,641.05 | 3,866,683,359.6 | 2,802,582,394.58 | 1,939,990,772.38 |
| 营业成本 | 434,450,480.81 | 1,839,024,242.87 | 1,378,689,027.98 | 990,265,217.06 |
| 税金及附加 | 14,004,530.11 | 59,379,099.79 | 42,356,350.74 | 30,571,815.47 |
| 销售费用 | 340,416,712.34 | 1,334,659,724.28 | 946,666,106.07 | 652,798,525.46 |
| 管理费用 | 76,351,112.27 | 292,408,155.97 | 204,787,268.13 | 127,881,009.21 |
| 研发费用 | 100,074,377.52 | 374,882,920.16 | 255,417,050.3 | 155,391,028.52 |
| 财务费用 | -10,480,572 | -33,670,783.47 | -25,333,408.64 | -16,916,823.34 |
| 其中:利息费用 | 1,348,244.49 | 6,585,354.54 | 4,925,948.23 | 3,042,639.5 |
| 其中:利息收入 | 12,050,671.27 | 41,586,965.49 | 29,058,111.58 | 19,834,756.44 |
| 加:公允价值变动收益 | -2,075,862.8 | -10,374,508.53 | 8,830,686.3 | 26,475,958.44 |
| 加:投资收益 | 10,844,203.15 | 44,117,533.05 | 29,201,190.43 | 15,603,427.69 |
| 资产处置收益 | 2,519,301.44 | 594,288.55 | 571,310.43 | 605,214.06 |
| 资产减值损失(新) | -30,325,909.56 | -73,496,801.64 | -39,609,027.43 | -35,781,742.51 |
| 信用减值损失(新) | -12,543,531.19 | -2,336,432.75 | -3,195,327.99 | -3,117,728.62 |
| 其他收益 | 19,928,778.05 | 38,408,690.12 | 18,337,167.59 | 6,924,954.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 182,477,172.29 | 592,578,045.27 | 421,411,663.13 | 290,429,092.38 |
| 加:营业外收入 | 1,321,616.04 | 6,207,721.77 | 2,221,462.43 | 1,782,309.49 |
| 减:营业外支出 | 104,001.51 | 2,928,934.83 | 1,525,417.89 | 1,490,081.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 183,694,786.82 | 595,856,832.21 | 422,107,707.67 | 290,721,320.21 |
| 减:所得税费用 | 21,513,432.4 | 70,430,488.46 | 26,522,001.68 | 23,833,328.14 |
| 六、净利润 | 162,181,354.42 | 525,426,343.75 | 395,585,705.99 | 266,887,992.07 |
| 持续经营净利润 | 162,181,354.42 | 525,426,343.75 | 395,585,705.99 | 266,887,992.07 |
| 归属于母公司股东的净利润 | 162,863,217.96 | 521,338,330.89 | 390,446,788.08 | 264,152,012.2 |
| 少数股东损益 | -681,863.54 | 4,088,012.86 | 5,138,917.91 | 2,735,979.87 |
| (一)基本每股收益 | 0.36 | 1.15 | 0.86 | 0.58 |
| (二)稀释每股收益 | 0.36 | 1.15 | 0.86 | 0.58 |
| 八、其他综合收益 | 1,764,577.67 | 244,782.98 | -3,478,206.83 | -807,503.12 |
| 归属于母公司股东的其他综合收益 | 1,764,577.67 | 244,782.98 | -3,478,206.83 | -807,503.12 |
| 九、综合收益总额 | 163,945,932.09 | 525,671,126.73 | 392,107,499.16 | 266,080,488.95 |
| 归属于母公司股东的综合收益总额 | 164,627,795.63 | 521,583,113.87 | 386,968,581.25 | 263,344,509.08 |
| 归属于少数股东的综合收益总额 | -681,863.54 | 4,088,012.86 | 5,138,917.91 | 2,735,979.87 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-27 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |